The Management of Urinary Tract Infections during the COVID-19 Pandemic: What Do We Need to Know?

Cai, Tommaso; Tascini, Carlo; Novelli, Andréa; Anceschi, Umberto; Bonkat, Gernot; Wagenlehner, Florian M. E.; Johansen, Truls E. Bjerklund

doi:10.3390/uro2010008

Cited by 3 publications

(4 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This review aims to update recurrent UTI management focusing on the risk factors identification and new therapeutic strategies to use in everyday clinical practice in light of antimicrobial stewardship. A search was performed in PubMed, Cochrane CENTRAL and Scopus databases for pertinent papers by using the following terms "recurrent urinary tract infections" AND "antimicrobial stewardship" AND/OR "risk factors" AND/OR "treatment" in line with our previous paper [9]. All references cited in relevant articles were also reviewed and analyzed.…”

Section: Search Of Evidencesmentioning

confidence: 99%

“…Several times, antimicrobials are prescribed inappropriately in outpatients affected by uncomplicated UTI [9,15]. Antimicrobial use, especially when inappropriate, is associated with the selection of antimicrobial-resistant organisms colonizing or infecting the urinary tract [3].…”

Section: What Is the Role Of Uncomplicated Uti Management In Antimicr...mentioning

confidence: 99%

“…Cai et al in a prospective study suggest stratifying all women affected by rUTI into three risk groups on the basis of LUTIRE nomogram findings [18] in order to evaluate the risk of a new symptomatic episode. In this sense and on the basis of recurrence risk, the patients should be treated as follows (Table 3): In the era of antibiotic resistance, an antibiotic-sparing approach represents an important and needed alternative treatment of uncomplicated cystitis in women [9,15]. Several antibiotic-sparing approaches have been proposed with interesting results.…”

Section: Use Of Spermicide Urinary Incontinencementioning

confidence: 99%

See 2 more Smart Citations

Recurrent UTI: Questions and Answers on Clinical Practice

Cai

Lanzafame

Tascini

2022

Uro

Self Cite

View full text Add to dashboard Cite

Recurrent urinary tract infection (rUTI) management is still a challenge due to the lack of a standard approach and due to the burden of diseases both on personal and societal aspects. Consultations for rUTIs in everyday clinical practice range from 1% to 6% of all medical visits with high social and personal associated costs, such as prescriptions, hospital expenses, days of sick leave due to the disease, and the treatment of related comorbidities. Recurrent UTIs are, then, associated with anxiety and depression due to treatment failures and symptomatic recurrences. Often urologists are asked to give practical recommendations to patients regarding the everyday management of recurrent UTIs. Here, we aim to give to the physicians managing UTI some helpful suggestions for their everyday clinical practice, on the basis of the recent evidence.

show abstract

Section: Search Of Evidencesmentioning

confidence: 99%

Section: What Is the Role Of Uncomplicated Uti Management In Antimicr...mentioning

confidence: 99%

Section: Use Of Spermicide Urinary Incontinencementioning

confidence: 99%

See 1 more Smart Citation

Recurrent UTI: Questions and Answers on Clinical Practice

Cai

Lanzafame

Tascini

2022

Uro

Self Cite

View full text Add to dashboard Cite

show abstract

“…Similarly, COVID-19 has brought about a variety of secondary infections and co-infections in patients. Many reports exhibited that secondary infections such as mucormycosis [ 13 , 14 , 15 ], blood coagulation [ 16 , 17 ], blood stream infections [ 18 , 19 ], urinary track infections (UTI) [ 20 , 21 , 22 ], and antibiotic resistance [ 23 , 24 , 25 , 26 ] were reported in COVID-19 patients during hospitalization or occurred post-infection. The coronavirus infection initially affects the lungs and disrupts the epithelial cell, leading to organ failure.…”

Section: Introductionmentioning

confidence: 99%

Artificial Intelligence: A Next-Level Approach in Confronting the COVID-19 Pandemic

et al. 2023

View full text Add to dashboard Cite

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which caused coronavirus diseases (COVID-19) in late 2019 in China created a devastating economical loss and loss of human lives. To date, 11 variants have been identified with minimum to maximum severity of infection and surges in cases. Bacterial co-infection/secondary infection is identified during viral respiratory infection, which is a vital reason for morbidity and mortality. The occurrence of secondary infections is an additional burden to the healthcare system; therefore, the quick diagnosis of both COVID-19 and secondary infections will reduce work pressure on healthcare workers. Therefore, well-established support from Artificial Intelligence (AI) could reduce the stress in healthcare and even help in creating novel products to defend against the coronavirus. AI is one of the rapidly growing fields with numerous applications for the healthcare sector. The present review aims to access the recent literature on the role of AI and how its subfamily machine learning (ML) and deep learning (DL) are used to curb the pandemic’s effects. We discuss the role of AI in COVID-19 infections, the detection of secondary infections, technology-assisted protection from COVID-19, global laws and regulations on AI, and the impact of the pandemic on public life.

show abstract

Clinical Experience with a Medical Device Containing Xyloglucan, Hibiscus, and Propolis for the Control of Acute Uncomplicated Urinary Tract Infection-like Symptoms

Ortega

Benito

Berrocal³

2022

Uro

View full text Add to dashboard Cite

Background: The development of drug resistance among causative agents has resulted in the need to change the paradigm toward alternative therapeutic approaches for uncomplicated urinary tract infections (UTIs). The objective of the present study was to evaluate the efficacy of an oral medical device containing xyloglucan, hibiscus, and propolis in clinical practice with a cohort of women from Switzerland with UTI-like symptoms and the administration of concomitant drugs. Materials and Methods: This work describes an observational, prospective, and multicenter study involving 103 women attending a primary care physician for a symptomatic episode, or recurrence, of acute uncomplicated cystitis between August 2018 and June 2019. Utipro®Plus was administered orally, with patients being prescribed two capsules per day for 5 days to control discomfort symptoms or one capsule per day for 15 consecutive days per month (followed by a 15-day break for a 3-month cycle) to prevent recurrences. Results: A total of 84 women (81.6%) did not require an additional consultation, whereas 17 (16.5%) required a second one. Inadequate treatment response was found in 7 women out of the 19 who required a further consultation (36.8%): 3 women with no history of cystitis (out of 13, 23.1%) and 4 with recurrent cystitis (out of 6, 66.7%). None of the women from the study reported an adverse event. Conclusions: The studied product containing xyloglucan, hibiscus, and propolis is safe and effective for the treatment of a broad spectrum of women with acute uncomplicated or recurrent UTI-like symptoms.

show abstract

The Management of Urinary Tract Infections during the COVID-19 Pandemic: What Do We Need to Know?

Cited by 3 publications

References 31 publications

Recurrent UTI: Questions and Answers on Clinical Practice

Recurrent UTI: Questions and Answers on Clinical Practice

Artificial Intelligence: A Next-Level Approach in Confronting the COVID-19 Pandemic

Clinical Experience with a Medical Device Containing Xyloglucan, Hibiscus, and Propolis for the Control of Acute Uncomplicated Urinary Tract Infection-like Symptoms

Contact Info

Product

Resources

About